Skip to content

Compugen gains US patent for immuno-oncology antibody

July 25, 2017

Thinly traded micro cap Compugen (CGEN +16.2%) is up on almost a 50% spike in volume in response to its announcement that the USPTO has issued a new method of use patent covering lead immuno-oncology therapeutic antibody candidate COM701 (U.S. Patent No. 9,714,289).

The patent was issued under the USPTO’s pilot program that provides early review for patent applications related to cancer immunotherapy in support of the White House Cancer Moonshot program.

COM701 is a humanized hybridoma antibody that binds to an immune checkpoint target called PVRIG.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: